Actively Recruiting
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Led by M.D. Anderson Cancer Center · Updated on 2026-04-17
77
Participants Needed
1
Research Sites
374 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.
CONDITIONS
Official Title
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with newly diagnosed AML
- Non-English speaking subjects will be included using verbal translation preparative sheet (VTPS) short form for consent
You will not qualify if you...
- Patients with contraindications to MR
- Patients allergic to MR contrast agents
- Patients with uncontrollable claustrophobia
- Patients who received more than minimal anti-leukemia treatment (more than leukapheresis, hydroxyurea, or Cytarabine >1 g/m2)
- Patients with secondary or relapsed AML or APL
- Patients with known extramedullary leukemia
- Females with a positive pregnancy test
- Patients younger than 18 years
- Patients weighing more than 400 pounds
- Patients with uncontrolled diabetes
- Cognitively impaired adults or prisoners
- Patients with estimated glomerular filtration rate (eGFR) less than 30
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
Dawid Schellingerhout, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here